198 related articles for article (PubMed ID: 36047131)
1. Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature.
Ma X; Fu X; Cui B; Lin H
Tohoku J Exp Med; 2022 Oct; 258(3):219-223. PubMed ID: 36047131
[TBL] [Abstract][Full Text] [Related]
2. Telitacicept: First Approval.
Dhillon S
Drugs; 2021 Sep; 81(14):1671-1675. PubMed ID: 34463932
[TBL] [Abstract][Full Text] [Related]
3. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
Fan Y; Gao D; Zhang Z
Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
[TBL] [Abstract][Full Text] [Related]
4. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
[TBL] [Abstract][Full Text] [Related]
5. Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review.
Fan Q; Ji H; Liu Y; Jia C; Zou L; Yang H
Lupus; 2024 Apr; 33(4):414-419. PubMed ID: 38320748
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.
Fan Q; Yang H; Liu Y
Z Rheumatol; 2024 Jun; 83(5):387-392. PubMed ID: 38157053
[TBL] [Abstract][Full Text] [Related]
7. B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept.
Ji L; Geng Y; Zhang X; Deng X; Song Z; Tan M; Tan Y; Qu C; Zhang Z
MedComm (2020); 2024 Apr; 5(4):e515. PubMed ID: 38525109
[TBL] [Abstract][Full Text] [Related]
8. Telitacicept for autoimmune nephropathy.
Cai J; Gao D; Liu D; Liu Z
Front Immunol; 2023; 14():1169084. PubMed ID: 37342346
[TBL] [Abstract][Full Text] [Related]
9. A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report.
Chen JW; Zhan JY; Liang SP; Wang XD; Lin CS; Xu Q
Int J Rheum Dis; 2023 Jul; 26(7):1417-1421. PubMed ID: 37218552
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
Huang L; Qian G; Zhang H; Li Q; Chen L; Tang X; Zhao H
Lupus; 2024 Feb; 33(2):172-175. PubMed ID: 38081170
[TBL] [Abstract][Full Text] [Related]
11. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
Wu D; Li J; Xu D; Merrill JT; van Vollenhoven RF; Liu Y; Hu J; Li Y; Li F; Huang C; Wang G; Li X; Zhao J; Zhao D; Huang C; Liu H; Wei W; Shi G; Lu F; Zuo X; Bi L; Li Z; Wang X; Zhang M; Tie N; Li J; Mo H; Fang J; Bao C; Zhang F
Ann Rheum Dis; 2024 Mar; 83(4):475-487. PubMed ID: 38129117
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study.
Jin HZ; Li YJ; Wang X; Li Z; Ma B; Niu L; Wang P; Pan HF; Li SD; Bao W; Wang G; Li XM; Chen Z
Lupus Sci Med; 2023 Nov; 10(2):. PubMed ID: 38007228
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.
Lv J; Liu L; Hao C; Li G; Fu P; Xing G; Zheng H; Chen N; Wang C; Luo P; Xie D; Zuo L; Li R; Mao Y; Dong S; Zhang P; Zheng H; Wang Y; Qin W; Wang W; Li L; Jiao W; Fang J; Zhang H
Kidney Int Rep; 2023 Mar; 8(3):499-506. PubMed ID: 36938094
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement.
Cheng J; Peng Y; Wu Q; Wu Q; He J; Yuan G
Clin Rheumatol; 2024 Jul; 43(7):2229-2236. PubMed ID: 38767710
[TBL] [Abstract][Full Text] [Related]
15. B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosus.
Spinelli FR; Barbati C; Cecarelli F; Morello F; Colasanti T; Vomero M; Massaro L; Orefice V; Alessandri C; Valesini G; Conti F
Arthritis Res Ther; 2019 Nov; 21(1):245. PubMed ID: 31752963
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study.
Chen R; Fu R; Lin Z; Huang C; Huang W
Lupus; 2023 Jan; 32(1):94-100. PubMed ID: 36416639
[TBL] [Abstract][Full Text] [Related]
17. Advances in therapeutic targets-related study on systemic lupus erythematosus.
Wang X; Zhang Q; Luo S; Zhang H; Lu Q; Long H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Nov; 46(11):1267-1275. PubMed ID: 34911862
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis.
Yao X; Ren Y; Zhao Q; Chen X; Jiang J; Liu D; Hu P
Eur J Pharm Sci; 2021 Apr; 159():105704. PubMed ID: 33440243
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial.
Sun L; Shen Q; Gong Y; Li Y; Lv Q; Liu H; Zhao F; Yu H; Qiu L; Li X; He X; Chen Y; Xu Z; Xu H
Lupus; 2022 Jul; 31(8):998-1006. PubMed ID: 35499216
[TBL] [Abstract][Full Text] [Related]
20. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
